CN112778156B - Bishydrazide structure compound, preparation method and application thereof - Google Patents
Bishydrazide structure compound, preparation method and application thereof Download PDFInfo
- Publication number
- CN112778156B CN112778156B CN201911089415.XA CN201911089415A CN112778156B CN 112778156 B CN112778156 B CN 112778156B CN 201911089415 A CN201911089415 A CN 201911089415A CN 112778156 B CN112778156 B CN 112778156B
- Authority
- CN
- China
- Prior art keywords
- hydrazine
- carbonyl
- carboxylic acid
- cyclohexane
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C241/04—Preparation of hydrazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C243/32—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a dihydrazide structure compound, a preparation method and application thereof. Specifically, the invention provides a bishydrazide structural compound shown in a formula I. The compound of the invention has the functions of enhancing the activity of intestinal stem cells, promoting the repair of intestinal epithelium and simultaneously reducing the expression of proinflammatory cytokines, thereby achieving the purpose of treating inflammatory intestinal diseases.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a dihydrazide structure compound, and a preparation method and application thereof.
Background
Inflammatory Bowel Disease (IBD) includes Ulcerative Colitis (UC) and Crohn's Disease (CD), characterized by recurrent episodes of inflammation of the digestive tract. In recent years, global incidence has seen a dramatic rise. The pathogenesis of IBD is not clear up to now and studies have shown to be associated with genetic, immunological, infectious and mental activities. Repeated attacks of disease can cause DNA damage and microsatellite instability of mucosal cells, leading to the development of colon cancer. It has been demonstrated that IBD patients are significantly more at risk of developing colon cancer than normal populations.
Of the inflammatory cytokines involved in the pathogenesis of IBD, IL-12 family members, in particular IL-23, have received extensive attention as being considered to be a central factor in the development of experimental inflammatory bowel disease models and human IBD. IL-23 activates CD4+ memory cells, CD8+ cells, NK cells and a few mononuclear macrophages/dendritic cells. By binding to the IL-23 receptor (IL-23R), secretion of IL-10, IL-17, INF-gamma, and the like is induced, thereby promoting the development of inflammation. Recent human genetic studies have established that IL-23R variation is associated with inflammatory responses in the small intestine (ileum CD) and large intestine (UC). The research finds that the IL-23 can maintain and expand the function of Th17 cells and aggravate intestinal inflammatory response.
In recent years, the advent of biological therapies (such as anti-TNF therapy) has greatly improved the treatment of IBD. However, there are still a large number of patients with refractory ulcers or refractory epithelial isomerism, making "mucosal healing" difficult for these patients. Mucosal healing indicates that IBD patients have restored intestinal epithelial structure and function, while also revealing a long-term remission or low-risk prognosis of surgery. The importance of restoring the structure and function of the intestinal epithelium has been identified in the treatment of IBD at present; mucosal healing has also reached consensus among clinicians and researchers as a standard goal of treatment. However, suitable therapeutic means are not yet available. The use of immunosuppressive agents and anti-cytokines improves the recurrence rate of IBD patients, however, there is still a lack of drugs that can cure IBD.
Therefore, there is an urgent need in the art to find key molecules in the pathogenesis and/or disease progression of IBD and to develop new compounds that can be used to treat IBD.
Disclosure of Invention
The invention aims to provide a class of bishydrazide structural compounds which can be used for treating IBD.
In a first aspect of the invention, there is provided a compound of formula I, an optical isomer or cis-trans isomer thereof, a pharmaceutically acceptable salt, hydrate, solvate, prodrug or an active metabolite thereof,
wherein, the first and the second end of the pipe are connected with each other,
X 1 ，X 2 ，X 3 each independently selected from the group consisting of: c (R) 1 ) 2 、NR 1 、CR 1 Or N;
and is
Is an aromatic or non-aromatic ring;
g is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, C 1 -C 6 Haloalkyl, or-L 1 -M；
Q is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, C 1 -C 6 Haloalkyl, or-L 1 -M；
When G is located at X 3 In the above, Q may be located at X 1 Or X 2 The above step (1);
when Q is at X 3 In the above, G may be located at X 1 Or X 2 The above step (1);
R 1 independently selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, or C 1 -C 6 A haloalkyl group;
L 1 independently selected from the group consisting of: -NHC (= O) -, -OC (= O) -, -NHS (= O) -, -OS (= O) -, -NHSO 2 -, -C (= O) NH-, -C (= O) O-, or-S (= O) NH-, -OS (= O) O-, or-SO 2 NH-；
M is independently selected from the group consisting of: c 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy, substituted or unsubstituted C 3 -C 20 Cycloalkyl, substituted or unsubstituted 3-20 heterocyclyl, substituted or unsubstitutedGeneration C 6 -C 14 Aryl, substituted or unsubstituted 6-14 membered heteroaryl; and-L 1 -M may optionally be further substituted by one or more halogens, 3-12 membered heterocyclyl or C 3-12 Cycloalkyl is substituted;
the substitution is selected from one or more of the following groups: halogen, nitro, cyano, C 1 -C 6 Alkyl radical, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino radical, C 2 -C 6 Alkenyl radical, C 2 -C 6 Haloalkenyl, C 3 -C 6 Cycloalkenyl radical, C 2 -C 6 Alkynyl, C 2 -C 6 Halogenated alkynyl, C 3 -C 6 Cycloalkyl alkynyl, C 6 -C 14 Aryl, 5-14 membered heterocyclyl, and said aryl, heteroaryl may optionally be further substituted with one or more substituents selected from the group consisting of: halogen, nitro, cyano, C 1 -C 6 Alkyl radical, C 1 -C 6 Haloalkyl, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkoxy radical, C 1 -C 6 An alkylamino group;
a is independently selected from the group consisting of: substituted or unsubstituted C 3-12 Cycloalkyl, substituted or unsubstituted 3-20 membered heterocyclyl, substituted or unsubstituted C 6 -C 14 Aryl, substituted or unsubstituted 6-14 membered heteroaryl; wherein the substitution is selected from one or more of the group consisting of: halogen, hydroxy, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylamino, hydroxymethyl or C 1 -C 6 A haloalkyl group;
k is independently selected from the group consisting of: r is 2 -C(＝O)NH-、R 2 -C(＝O)O-、-C(＝O)NH-R 2 、-C(＝O)O-R 2 ，R 2 Independently selected from the group consisting of: hydrogen, C 1 -C 6 Alkyl radical, C 6 -C 14 Aryl, 6-14 membered heteroaryl.
In another preferred embodiment, the compound, its optical isomer or cis-trans isomer, pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof has the structure shown in formula II
Wherein the content of the first and second substances,
X 1 ，X 2 ，X 3 each independently selected from: CR 1 Or N;
R 1 independently selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, halomethyl or-L 1 -M；
L 1 Independently selected from the group consisting of: -NHC (= O) -, -OC (= O) -, -NHS (= O) -, -OS (= O) -, -NHSO) - 2 -, -C (= O) NH-, -C (= O) O-, or-S (= O) NH-, -OS (= O) O-or-SO 2 NH-；
M is independently selected from the group consisting of: c 2 -C 4 Alkyl radical, C 1 -C 6 Alkoxy, substituted or unsubstituted C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted 6-20 membered fused heterocycle, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted 5-6 membered heteroaryl; said M may be further substituted by one or more halogens, 3-12 membered heterocyclic groups or C 3-12 Cycloalkyl substituted; and the substitution is selected from one or more of the group consisting of: halogen, nitro, cyano, C 1 -C 6 Alkyl radical, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino radical, C 2 -C 6 Alkenyl radical, C 2 -C 6 Haloalkenyl, C 3 -C 6 Cycloalkenyl radical, C 2 -C 6 Alkynyl, C 2 -C 6 Haloalkynyl, C3-C6 cycloalkyl-C3-C6 alkynyl, phenyl, or 5-to 14-membered heterocyclyl, andthe phenyl, 5-14 membered heterocyclyl may optionally be further substituted with one or more substituents selected from the group consisting of: halogen, nitro, cyano, C 1 -C 6 Alkyl radical, C 1 -C 6 Haloalkyl, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkoxy, or C 1 -C 6 An alkylamino group;
a is independently selected from the group consisting of: substituted or unsubstituted C 3-12 Cycloalkyl, substituted or unsubstituted C 6 -C 14 Aryl, or substituted or unsubstituted 6-14 membered heteroaryl; wherein the substitution is selected from one or more of the group consisting of: halogen, hydroxy, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylamino, hydroxymethyl or halomethyl;
k is independently selected from the group consisting of: -C (= O) NH-R 2 、-C(＝O)O-R 2 ，R 2 Independently selected from the group consisting of: hydrogen, C 1 -C 6 Alkyl radical, C 6 -C 14 Aryl or 6-14 membered heteroaryl.
In another preferred embodiment, the compound, its optical isomer or cis-trans isomer, pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof has the structure shown in the following formula III,
wherein G, Q, A and K are as defined above.
In another preferred embodiment, the compound, its optical isomer or cis-trans isomer, pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof has the structure shown in formula IV,
wherein G, Q, A and K are as defined above.
In another preferred embodiment, the compound, its optical isomer or cis-trans isomer, pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof has the structure shown in the following formula V,
wherein G, Q, A and K are as defined above.
In another preferred embodiment, the compound is selected from the following compounds:
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid methyl ester;
2- (2- (4- (3-methylbutanamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4-acetamidobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4-benzoylaminobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclohexanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclopropylcarbamoyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (trifluoromethoxy) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (tert-butyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (trifluoromethyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (oxazol-5-yl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (3-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (2-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2, 4-dichlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (6-chloronicotinyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (6-bromonicotinoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) -3-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) -2-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (2-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (3-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (3- (cyclopropanecarboxamido) -4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] hept-5-ene-2-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) benzoic acid;
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclopropane-1-carboxylic acid;
4, 5-dibromo-2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid;
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid;
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid;
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) benzoic acid;
3- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
3- (2- (4-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
3- (2- (3-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
3- (2- (2-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
3- (2, 4-dichlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid;
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -2-naphthoic acid.
In a second aspect of the present invention, there is provided a process for preparing a compound of formula I, an optical isomer or a cis-trans isomer thereof, a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug or an active metabolite thereof as described in the first aspect, comprising the steps of:
in a first inert solvent, a 2 Reacting the compound with a compound b, optionally further reacting to obtain a compound I;
wherein X 1 ，X 2 ，X 3 G, Q, A, K are as defined above.
In another preferred embodiment, the further reaction refers to substitution with halogenated alkane, or condensation reaction with alcohol or amine to obtain compound I; the alcohol is C 1 -C 6 alkyl-OH, said amine being C 1 -C 6 alkyl-NH 2 Or C 1 -C 6 alkyl-N-C 1 -C 6 An alkyl group.
In another preferred embodiment, the first inert solvent is selected from: CH (CH) 3 CN, toluene, xylene, dichloromethane, DMF, or combinations thereof.
In another preferred embodiment, the salts are prepared by reacting a compound of formula I with the free base or acid with a chemically equivalent or excess of the acid (inorganic or organic) or base (inorganic or organic) in a suitable solvent or solvent composition.
In another preferred embodiment, the process for preparing a compound of formula I, its optical isomer or cis-trans isomer, pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof, further comprises the steps of:
in a second inert solvent, compound a 1 With hydrazine hydrate to form the compound a 2 ；
Wherein, X 1 ，X 2 ，X 3 G, Q are as defined above.
In another preferred embodiment, the second inert solvent is an alcohol, preferably C 1 -C 6 An alkyl alcohol, more preferably methanol or ethanol.
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the first aspect, an optical isomer or a cis-trans isomer thereof, a pharmaceutically acceptable salt, hydrate, solvate, prodrug or active metabolite thereof; and a pharmaceutically acceptable carrier.
In a fourth aspect of the present invention, there is provided a use of the compound of the first aspect, an optical isomer or a cis-trans isomer thereof, a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, or an active metabolite thereof, or a use of the pharmaceutical composition of the third aspect in preparation of a medicament and a pharmaceutical composition for treating or preventing inflammatory bowel disease.
In another preferred embodiment, the inflammatory bowel disease comprises crohn's disease or Behcet's disease with intestinal lesions, ulcerative colitis, bleeding rectal ulcers and ileocolitis.
In another preferred embodiment, the treatment comprises: promoting mucosal healing, restoring intestinal epithelial structure, or a combination thereof.
In another preferred embodiment, the treatment comprises: promoting the activity of an intestinal stem cell, reducing the expression of a proinflammatory cytokine, or a combination thereof.
In a fifth aspect of the invention, there is provided a method for inhibiting IL-23 and upregulating cyclinD1 in vitro comprising the steps of: contacting a compound according to the first aspect of the invention, an optical isomer or a cis-trans isomer thereof, a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug or an active metabolite thereof with a somatic cell (or tissue), thereby inhibiting IL-23 and up-regulating cyclinD1.
In another preferred embodiment, said inhibiting IL-23 includes inhibiting the formation of IL-23miRNA and inhibiting the expression of IL-23 protein.
In another preferred embodiment, the up-regulation of cyclinD1 comprises promotion of the formation of cyclinD1 miRNA and promotion of the expression of cyclinD1 protein.
In another preferred embodiment, the somatic cell is selected from the group consisting of: macrophages, intestinal cells (including intestinal stem cells, intestinal epithelial cells), or a combination thereof.
In another preferred embodiment, the somatic cell is from a rodent (e.g., mouse, rat), or primate (e.g., human).
In a fifth aspect of the present invention, there is provided a method of treating inflammatory bowel disease, comprising the steps of: administering to a subject in need thereof a compound, an optical isomer or a cis-trans isomer thereof, a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug or an active metabolite thereof according to the first aspect of the present invention, or a pharmaceutical composition according to the third aspect.
In another preferred embodiment, the inflammatory bowel disease comprises crohn's disease or Behcet's disease with intestinal lesions, ulcerative colitis, bleeding rectal ulcers and ileocolitis.
In another preferred embodiment, the subject is a mammal, preferably a human.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
FIG. 1 shows Compound A 1 For mouse knotTherapeutic effect in the enteritis model.
FIG. 2 shows Compound A 1 At both concentrations, the plasma levels of the orally administered mice varied.
FIG. 3 shows Compound A 1 Promoting growth of mouse-derived intestinal organoids.
Detailed Description
The inventor unexpectedly develops a class of bishydrazide structural compounds which can inhibit IL-23 and can up-regulate cyclinD1 through extensive and intensive research. The compound not only can inhibit the over-activated intestinal inflammatory reaction and immune response so as to obviously reduce the colon inflammation of IBD mice, but also can effectively promote the healing of intestinal mucosa and maintain the steady state, thereby being effectively and synergistically used for treating inflammatory intestinal diseases. The present invention has been completed based on this finding.
Term(s) for
The term "alkyl" refers to a straight or branched chain alkyl group containing 1 to 18 carbon atoms, especially 1 to 6 carbon atoms. Typical "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, isopentyl, heptyl, 4-dimethylpentyl, octyl, 2, 4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl and the like. Term "(C) 1 -C 6 ) Alkyl "refers to straight or branched chain alkyl groups including from 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl. "substituted alkyl" means an alkyl group which is substituted at one or more positions, especially 1 to 4 substituents, and may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. monohalogen substituents or polyhalo substituents, the latter being trifluoromethyl or containing Cl 3 Alkyl of (e.g., = O), nitrile group, nitro group, oxygen (e.g., = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above-mentioned typical substituents such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring may be optionally substituted.
The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing 2 to 18 carbon atoms, at least one carbon-carbon double bond. Term "(C) 2 -C 6 ) Alkenyl "means a straight-chain or branched group having 2 to 6 carbon atoms and at least one carbon-carbon double bond, such as vinyl, propenyl, 2-propenyl, (E) -2-butenyl, (Z) -2-butenyl, (E) -2-methyl-2-butenyl, (Z) -2-methyl-2-butenyl, 2, 3-dimethyl-2-butenyl, (Z) -2-pentenyl, (E) -1-pentenyl, (E) -2-pentenyl, (Z) -2-hexenyl, (E) -1-hexenyl, (Z) -1-hexenyl, (E) -2-hexenyl, (Z) -3-hexenyl, (E) -1, 3-hexadienyl, 4-methyl-3-pentenyl or norbornene. "substituted alkenyl" means that one or more positions in the alkenyl group are substituted, especially 1 to 4 substituents, which may be substituted at any position. Exemplary substitutions include, but are not limited to, oneOne or more of the following groups: such as hydrogen, deuterium, halogen (e.g. monohalogen substituents or polyhalo substituents, the latter being trifluoromethyl or containing Cl 3 Alkyl of (e.g., = O), nitrile group, nitro group, oxygen (e.g., = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above-mentioned typical substituents such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring may be optionally substituted.
The term "alkynyl" refers to a substituent containing from 2 to 18 carbon atoms, at least one carbon-carbon triple bond, of a straight or branched hydrocarbon group. Typical groups include ethynyl. Term "(C) 2 -C 6 ) Alkynyl means a straight or branched chain radical having from 2 to 6 carbon atoms and at least one carbon-carbon double bond, e.g. ethynyl, 1-propynyl, 2-propynylAlkynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl. "substituted alkynyl" means that one or more positions in the alkynyl group are substituted, especially 1 to 4 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g., monohalogen substituents or polyhalo substituents, the latter such as trifluoromethyl or containing Cl 3 Alkyl of (e.g., = O), nitrile group, nitro group, oxygen (e.g., = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. Typical substituents may be optionally substituted.
The term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon group comprising 1 to 4 rings containing 3 to 8 carbon atoms in each ringExamples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or norbornane, containing from 3 to 18 carbon atoms, especially from 3 to 14 carbon atoms. "substituted cycloalkyl" means that one or more positions in the cycloalkyl group are substituted, especially 1 to 4 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. monohalogen substituents or polyhalo substituents, the latter being trifluoromethyl or containing Cl 3 Alkyl of (e.g., = O), nitrile group, nitro group, oxygen (e.g., = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above typical substituents may be optionally substituted. Typical substitutions also include spiro, bridged or fused ring substituents, especially spirocycloalkyl, spiroalkenyl, spirocyclicHeterocyclic ring (excluding heteroaromatic ring), bridged cycloalkyl, bridged alkenyl, bridged heterocyclic ring (excluding heteroaromatic ring), fused cycloalkyl, fused alkenyl, fused heterocyclic group, or fused aromatic cyclic group, the above cycloalkyl, cycloalkenyl, heterocyclic group, and heterocyclic aryl group may be optionally substituted.
The term "cycloalkenyl" refers to a partially unsaturated cyclic hydrocarbon compound group comprising 1 to 4 rings containing 3 to 8 carbon atoms in each ring, for example containing 3 to 18 carbon atoms, especially 3 to 14 carbon atoms. Typical cycloalkenyl groups are cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. "substituted cycloalkenyl" means that one or more positions in a cycloalkyl group are substituted, especially 1 to 4 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. monohalogen substituents or polyhalo substituents, the latter being trifluoromethyl or containing Cl 3 Alkyl) nitrile group, nitro group, oxygen (e.g = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d Can independently representHydrogen, deuterium, alkyl, cycloalkyl, heterocyclic or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above typical substituents may be optionally substituted. Typical substitutions also include bridged, spiro or fused ring substituents, especially spirocycloalkyl, spiroalkenyl, spiroheterocyclic (excluding heteroaromatic rings), fused ring alkyl, fused ring alkenyl, fused ring heterocyclic or fused ring aromatic ring groups, which may be optionally substituted.
The term "cycloalkylalkynyl" refers to cycloalkyl-substituted alkynyl groups, including C3-C8 cycloalkyl-C ≡ C-R a ，R a May independently represent none, hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, for example: cyclopropyl acetylene, cyclobutyl acetylene, cyclopentyl acetylene, cyclohexyl acetylene. Wherein, cycloalkyl may be substituted, and the substituents may be as in the term "cycloalkyl".
The term "aryl" refers to an aromatic cyclic hydrocarbon group having 1 to 5 rings, for example containing 6 to 18 carbon atoms, especially 6 to 14 carbon atoms. In particular monocyclic and bicyclic radicals, such as phenyl, biphenyl or naphthyl. Where the aromatic ring contains two or more aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be linked by a single bond (e.g., biphenyl), or fused (e.g., naphthalene, anthracene, etc.). "substituted aryl" means that one or more positions in the aryl group are substituted, especially 1 to 3 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. mono-or polyhalo-substituents, the latter being e.g. trifluoromethyl or containing Cl 3 Alkyl) nitrile group, nitro group, oxygen (e.g = O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(＝O)R e 、S(＝O) 2 R e 、P(＝O) 2 R e 、S(＝O) 2 OR e ,P(＝O) 2 OR e 、NR b R c 、NR b S(＝O) 2 R e 、NR b P(＝O) 2 R e 、S(＝O) 2 NR b R c 、P(＝O) 2 NR b R c 、C(＝O)OR d 、C(＝O)R a 、C(＝O)NR b R c 、OC(＝O)R a 、OC(＝O)NR b R c 、NR b C(＝O)OR e ,NR d C(＝O)NR b R c 、NR d S(＝O) 2 NR b R c 、NR d P(＝O) 2 NR b R c 、NR b C(＝O)R a Or NR b P(＝O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r is e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above typical substituents may be optionally substituted. Typical substitutions also include fused ring substituents, especially fused ring alkyl, fused ring alkenyl, fused ring heterocyclyl or fused ring aromatic ring groups, which can be optionally substituted.
The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms (preferably 1 or 2), 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, nitrogen and sulfur. The heteroaryl group is preferably a 5-to 10-membered ring, more preferably a 5-or 6-membered ring, for example, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, purine, carbazole, indolyl, indazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, isomerized quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl or naphthyridinyl, tetraazazolyl, and the like. "heteroaryl" may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, carboxy, and carboxylate.
The term "halogen" or "halo" refers to chlorine, bromine, fluorine, iodine.
"haloalkyl" means straight or branched chain haloalkyl, such as "C 1 -C 6 Haloalkyl "which means a straight or branched chain haloalkyl group having 1 to 6 carbon atoms containing one or more of the same or different halogen atoms, including without limitation-CH 2 Cl、-CHCl 2 、-CCl 3 、-CH 2 F、-CHF 2 、-CF 3 、-CH 2 Br、-CHBr 2 、-CBr 3 、CF 3 CH 2 、CCl 3 CH 2 、CBr 3 CH 2 。
The term "alkoxy" refers to a straight or branched chain alkoxy group, such as "C1-C6 alkoxy", which refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including without limitation methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like. C1-C4 alkoxy is preferred.
The term "haloalkoxy" refers to a halogen-substituted straight or branched chain alkoxy group, such as "C1-C6 haloalkoxy", which refers to a straight or branched chain haloalkoxy group having 1 to 6 carbon atoms, including without limitation chloromethoxy, chloroethoxy, chloropropoxy, chloroisopropoxy, chlorobutoxy, bromomethoxy, bromoethoxy, bromopropoxy, bromoisopropoxy, bromobutoxy, and the like.
The term "alkylamino" refers to "an amino-substituted straight or branched chain alkyl group, such as" C1-C6 alkylamino ", which refers to an amino-substituted straight or branched chain alkyl group having 1 to 6 carbon atoms, including without limitation H 2 N-CH 2 -、H 2 N-CH 2 CH 2 -、H 2 N-CH 2 CH 2 CH 2 -、H 2 N-CH(CH 3 )CH 2 -and the like.
The term "haloalkenyl" refers to a substituent containing 2 to 18 carbon atoms with at least one carbon-carbon double bond. Term "(C) 2 -C 6 ) Haloalkenyl "refers to a straight or branched chain group of 2 to 6 carbon atoms, having at least one carbon-carbon double bond, and one or more of the same or different halogen atoms, including-CH = CHCl, -CH = CCl 2 、-CH＝CHF、-CH＝CF 2 、-CH＝CHBr、-CH＝CBr 2 、-CH＝CH-CH 2 F、-CH＝CHCHF 2 、-CH＝CH-CF 3 、-CH＝CHCH 2 Br、-CH＝CHCHBr 2 、-CH＝CHCBr 3 And so on.
The term "haloalkynyl" refers to a substituent group containing 2 to 18 carbon atoms with at least one carbon-carbon triple bond. Term "(C) 2 -C 6 ) Haloalkynyl "refers to a straight or branched chain group containing 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and one or more of the same or different halogen atoms, including-C.ident.CCl, -C.ident.CF, -C.ident.CBr, -C.ident.C-CH 2 F、-C≡CCHF 2 、-C≡C-CF 3 、-C≡CCH 2 Br、-C≡CCHBr 2 、-C≡CCBr 3 And the like.
The term "carboxy" refers to-COOH.
The term "hydroxymethyl" refers to-CH 2 OH。
The term "condensation reaction" means that the carboxylic acid compound obtained in the present invention is reacted with an alcohol or an amine in the presence of a condensing agent; the condensing agent may use a conventional condensing agent well known in the art, for example: DMAP, EDCI, HOBT, HOAT, HATU, HBTU, etc.
Unless otherwise stated, it is assumed that any heteroatom that is not in a valence state has sufficient hydrogen to replenish its valence state.
The salts which the compounds of the invention may form are also within the scope of the invention. Unless otherwise indicated, the compounds of the present invention are understood to include salts thereof. The term "salt" as used herein, means a salt formed from an inorganic or organic acid and a base in either acid or base form. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are useful, e.g., in isolation or purification steps of the preparation. The compounds of the invention may form salts, for example, by reacting compound I with an amount of acid or base, e.g. an equivalent amount, and then precipitating out in a medium, or by lyophilization in aqueous solution.
As described herein, the compounds of the present invention can be substituted with any number of substituents or functional groups to extend their inclusion range. In general, the term "substituted", whether appearing before or after the term "optional", in the formula of the present invention including substituents, means that the hydrogen radical is replaced with a substituent of the indicated structure. When a plurality of the specified structures are substituted at a position with a plurality of the specified substituents, each position of the substituents may be the same or different. The term "substituted" as used herein includes all permissible substitutions of organic compounds. In a broad sense, permissible substituents include acyclic, cyclic, branched, unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds.
In the present invention, the heteroatom nitrogen may have a hydrogen substituent or any permissible organic compound described hereinabove to supplement its valence state.
In the present specification, inflammatory bowel disease refers not only to strictly inflammatory bowel diseases such as crohn's disease and ulcerative colitis but also to inflammatory bowel diseases in a broad sense including intestinal lesions with Behcet's disease, bleeding rectal ulcers, ileocele, intestinal tuberculosis, ischemic enteritis, drug colitis, radiation enteritis, infectious enteritis, and the like.
Furthermore, the present invention is not intended to be limited in any way as to the permissible substitution of organic compounds. The present invention recognizes that the combination of substituents and variable groups is excellent in the treatment of diseases, such as infectious diseases or proliferative diseases, in the form of stable compounds. The term "stable" as used herein refers to compounds that are stable enough to maintain the structural integrity of the compound when tested for a sufficient period of time, and preferably are effective for a sufficient period of time, and are used herein for the purposes described above.
Metabolites of the compounds referred to herein and pharmaceutically acceptable salts thereof, as well as prodrugs that can be converted in vivo into the structures of the compounds referred to herein and pharmaceutically acceptable salts thereof, are also included within the scope of the present invention.
Active ingredient
As used herein, the terms "compound of the present invention", or "bishydrazide structural class of compounds of the present invention", which are used interchangeably, refer to compounds of formula I. The term also includes compounds of formula I, optical isomers or cis-trans isomers thereof, pharmaceutically acceptable salts, hydrates, solvates, prodrugs, or active metabolites thereof.
The term "pharmaceutically acceptable salts" refers to salts of the compounds of the present invention with acids or bases, which are suitable for use as medicaments. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is that formed by reacting a compound of the present invention with an acid. Suitable acids for forming the salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and the like; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid, etc. Another preferred class of salts are those of the compounds of the invention with bases, for example alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., magnesium or calcium salts), ammonium salts (e.g., lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, triethanolamine salts, and amine salts formed from morpholine, piperazine, lysine, respectively.
The term "solvate" refers to a compound of the present invention coordinated to solvent molecules to form a complex in a specified ratio. "hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.
In addition, the compound also comprises a prodrug of the bishydrazide structure shown in the formula I. The term "prodrug" includes a class of compounds which are biologically active or inactive in nature and which, when administered by an appropriate method, undergo a metabolic or chemical reaction in the body to convert the compound to formula I, or a salt or solution of a compound of formula I. The prodrugs include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo, phosphoramide, glucoside, ether, acetal forms of the compounds.
Preparation method
The process for the preparation of the compounds of formula I according to the invention is described in more detail below, without restricting the invention in any way. The compounds of the present invention may also be conveniently prepared by optionally combining various synthetic methods described in the present specification or known in the art, and such combinations may be readily carried out by those skilled in the art to which the present invention pertains.
In general, in the preparative scheme, each reaction is usually carried out in an inert solvent at 0 ℃ or room temperature to reflux temperature (e.g., 0 ℃ to 160 ℃, preferably 0 ℃ to 120 ℃). The reaction time is usually 0.1 to 60 hours, preferably 0.5 to 48 hours.
The following general preparative routes may be used to synthesize the compounds of the present invention having the structure of formula I:
in a first inert solvent, compound a 2 Reacting with the compound b to obtain the compound I.
In the present invention, the compound a2 can be prepared by the following steps:
in the above reaction formulae, each group is as defined above.
Pharmaceutical compositions and methods of administration
Because the compounds of the present invention have the effects of inhibiting IL-23 (for example, inhibiting IL-23 mRNA) and up-regulating cyclinD1 (for example, increasing cyclinD1 mRNA), the compounds of the present invention, optical isomers or cis-trans isomers, pharmaceutically acceptable salts, hydrates, solvates, prodrugs or active metabolites thereof, and the pharmaceutical compositions containing the compounds of the present invention as the main active ingredients can be used for treating, preventing and relieving IBD.
The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-1000mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g. tween, etc.)
) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) Disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary amine compounds; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such a composition may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, and oils, in particular, cottonseed, groundnut, corn germ, olive, castor, and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if desired.
The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
In the case of pharmaceutical compositions, a safe and effective amount of a compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the administration is a pharmaceutically acceptable and effective dose, and the daily dose for a human of 60kg body weight is usually 1 to 2000mg, preferably 50 to 1000mg. Of course, the particular dosage will also take into account such factors as the route of administration, the health of the patient, and the like, which are within the skill of the skilled practitioner.
The main advantages of the invention include:
1. the dihydrazide structure compound provided by the invention has the effects of enhancing the activity of intestinal stem cells, promoting the repair of intestinal epithelium and simultaneously reducing the expression of proinflammatory cytokines, thereby achieving the purpose of treating Inflammatory Bowel Diseases (IBD).
2. The bishydrazide structural compound of the invention can inhibit IL-23mRNA and can up-regulate cyclinD1mRNA, thereby being capable of treating IBD synergistically and more efficiently.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
EXAMPLE 1 Compound A 1 The synthesis of (2):
the first step is as follows: after dissolving Compound 1 (500 mg) in DCM (10 mL), the temperature was lowered to 0 ℃ and Compound 3 (348 mg) was added, and the mixture was slowly warmed to room temperature and kept at room temperature for reaction for 30min. The reaction was quenched with water, extracted with ethyl acetate, concentrated under reduced pressure, and the residue was extracted with petroleum ether: ethyl acetate =5: purification by column chromatography using 1 as eluent gave compound 2 (610 mg, 84% yield). 1 HNMR(400MHz,CDCl3):δ8.00(d,J＝8.8Hz,2H),7.60(d,J＝8.8Hz,2H),3.90(s,3H),1.53(m,1H),1.12(m,2H),0.88(m,2H)。
The second step: compound 2 (400 mg) was dissolved in CH3CH2OH (25 mL), and hydrazine hydrate (5 mL) was added to conduct a reaction at reflux for 4h. After completion of the reaction, concentration under reduced pressure and washing of the solid with ice water, followed by recrystallization from ethanol gave compound 4 (120 mg, 40% yield). 1 HNMR(400MHz,CD3OD):δ7.74(d,J＝9.2Hz,2H),7.65(d,J＝9.2Hz,2H),1.89(s,3H),1.77(m,1H),1.28(s,2H),0.95(m,2H),0.87(m,2H)。
The third step: dissolve Compound 5 (352 mg) in CH 3 CN (15 mL), heated to reflux, then Compound 4 (500 mg) was added and the reaction was maintained at reflux for 30min. After the reaction is finished, pumpingFiltering to obtain solid, washing the solid with CH3CN, and vacuum drying at 70 deg.C for 2 hr to obtain compound A 1 (605 mg, yield 71%). 1 H NMR(400MHz,DMSO-d6):δ10.45(s,1H),10.11(s,1H),9.64(s,1H),7.82(d,J＝6.0Hz,2H),7.66(d,J＝5.6Hz,2H),2.87(m,1H),2.12(m,1H),2.06(m,1H),1.97(m,1H),1.80(m,1H),1.72(m,1H),1.65(m,1H),1.57(m,1H),1.41(m,2H),1.29(m,1H),0.82(m,5H)； 13 CNMR(125MHz,DMSO-d 6 ):δ175.37,173.35,172.54,165.38,142.71,128.84,127.26,118.56,42.33,40.72,28.23,25.60,24.51,22.83,15.15,7.84；LRMS(ESI):397.5(M+Na) + ,372.7(M-H) - ；HRMS(ESI):calcd for C 19 H 22 N 3 O 5 (M-H) - :372.1565,found:372.1561.
EXAMPLE 2 Compound A 2 Synthesis of (2)
Mixing the compound A 1 (100 mg) and K 2 CO 3 (74 mg) was dissolved in DMF (2 mL) and CH was added dropwise with stirring 3 I, stirring was continued overnight. After the reaction was completed, the reaction was quenched with water, extracted with EA, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was extracted with petroleum ether: ethyl acetate =5: purifying the 1-bit eluent by column chromatography to obtain a compound A 2 (90 mg, yield 85%). 1 H NMR(400MHz,DMSO-d 6 ):δ10.37(s,1H),7.57(d,J＝8.8Hz,1H),7.20(d,J＝8.8Hz,1H),3.12(s,3H),2.94(s,1H),1.75(m,1H),1.45(m,3H),1.19(m,2H),0.88(m,4H),0.79(d,J＝5.6Hz,4H).LRMS(ESI):387.0(M) + 。
Examples 3-37 Compound A 3 -A 37 Synthesis of (2)
Compound A was synthesized by following the procedure of examples 1-2 by substituting the substrate of example 1 with the corresponding substrate 3 -A 37 。
The structures and the characterization results of the compounds A3-A37 are as follows:
TABLE A
Example 38 animal and cell experiments
1. Experimental materials
Cells and animals
HCT116 cells and raw264.7 cells were supplied from the institute of china academy of sciences cell bank; the intestinal organoids are derived from intestinal crypt culture isolated from Lgr5-EGFP mice; the Lgr5-EGFP mouse is given by the Hua Jiang subject group of the Compound denier radio medicine institute, the genetic background is C57/BL6, and the Lgr5-EGFP mouse is bred in the second floor SPF animal house of the experimental animal center of the pharmaceutical institute of Compound denier university.
Primary reagent
2. Experimental method
A. Cell assay
Screening the activity of the compound:
detection of IL-23 mRNA:
all test compounds were made up in DMSO to a concentration of 50mM in stock and stored at-20 ℃ in a refrigerator. Raw264.7 cells are inoculated in a 12-well plate, the cell density is about 70-80% after 24 hours, compounds with different dilution ratios are added, 20 mu l (namely 0.5 mu g/ml) of LPS is added into each well after 1 hour of medicine addition, and the culture plate is shaken gently and mixed evenly. Blank groups were not added. After 6 hours, the medium was discarded, washed 3 times with ice-cold PBS buffer, 1ml Trizol was added, and the mixture was allowed to stand for 10min, the lysate was collected, the supernatant was obtained by centrifugation, 1/5 volume of chloroform was added, the mixture was shaken for 1min, and the mixture was allowed to stand for 3min, and 12000g was centrifuged at 4 ℃. And (3) adding isopropanol with the same volume into the supernatant, uniformly mixing, standing for 10min, centrifuging for 12000xg, and 10min. Removing supernatant, washing precipitate with 70% ethanol, centrifuging at 7500g for 5min, drying precipitate, and adding 20 μ L DEPC water. The RNA concentration of the sample was measured and adjusted to 100-1000 ng/. Mu.L, and changes in IL-23mRNA levels were detected using commercially available reverse transcription kits as well as SYBR-qPCR kits.
(1) Reverse transcription to synthesize cDNA
According to the instructions of the reverse transcription kit, the following mixture was prepared in an RNase free centrifuge tube and gently pipetted and mixed. Incubate at 42 ℃ for 2min. The reverse transcription reaction program is as follows, stage 1, 25 ℃,5min; stage 2 ℃,30min; stage 3, at 85 ℃ for 5min; stage 4,4 ℃, hold, product-20 ℃ storage, or used directly for RT-qPCR.
(2) RT-PCR amplification
The primer sequences involved in Real-Time PCR are as follows:
by using
Method for analyzing data and calculating
The value of (A) is the fold of the expression of the target gene in the experimental group relative to the control group.
Detection of cyclind1 mRNA:
the colorectal cancer HCT116 cell line was subjected to compound screening using McCOY's 5A medium containing 10% FBS. Inoculating the cells into a 12-hole plate, and enabling the density of adherent cells to be 70% -80% on the next day. mu.L of stock solution (50 mM) was taken in 1ml of medium, and 50. Mu.M of drug-containing medium (control group 0.1% DMSO medium) was prepared. Discarding the original culture medium, adding the medicated culture medium, and culturing at 37 deg.C for 6 hr. Discarding the culture medium, washing with ice-cold PBS buffer for 3 times, adding 1ml Trizol, standing for 10min, collecting lysate, centrifuging to obtain supernatant, adding 1/5 volume of chloroform, shaking for 1min, standing for 3min, and centrifuging at 4 deg.C for 12000Xg. And (3) adding isopropanol with the same volume into the supernatant, uniformly mixing, standing for 10min, centrifuging for 12000xg, and 10min. Removing supernatant, washing precipitate with 70% ethanol, centrifuging at 7500Xg for 5min, drying precipitate, and adding 20 μ L DEPC water. The RNA concentration of the sample is detected and adjusted to 100-1000 ng/. Mu.L, and the mRNA level change of the cyclinD1 is detected by using a commercial reverse transcription kit and a SYBR-qPCR kit.
(1) Reverse transcription to synthesize cDNA
According to the instructions of the reverse transcription kit, the following mixture was prepared in an RNase free centrifuge tube and gently pipetted and mixed. Incubate at 42 ℃ for 2min. The reverse transcription reaction program is as follows, stage 1 is at 25 ℃ for 5min; stage 2 ℃,30min; stage 3, 85 ℃ for 5min; stage 4 ℃, hold, product-20 ℃ storage, or direct use for RT-qPCR.
(2) RT-PCR amplification
The primer sequences involved in Real-Time PCR are as follows:
the desired fragment of cDNA was amplified using a CFX100 fluorescent quantitative PCR instrument from Bio-Rad.
Collecting instrument data, using 2 -△△Ct Method to analyze data, calculate 2 -△△Ct The value of (b) is the multiple of the target gene expression of the experimental group relative to the control group.
B. Animal experiments
Animal breeding and gene identification
Propagation of Lgr5-EGFP mice
Mouse genotype identification
Genotype identification of Lgr5-EGFP mice
Gene identification sequence
PCR was carried out as follows:
the reaction program was set up as indicated.
1. Establishment of mouse acute IBD model and compound A 1 In vivo efficacy test
The experimental groups were set as a control group, a model group, and a mesalazine administration group, A 1 10mg/kg administration group and Compound A 1 Five groups of 8 male C57/BL6 mice of 8 weeks of age per group, except the control group, were given 3% dextran sulfate sodium salt (DSS) water ad libitum, reconstituted every other day and replaced for 7 days.
Compound A 1 Dissolving in DMSO to obtain mother solution, dissolving in ultrapure water to obtain 4% DMSO aqueous solutions with final concentrations of 1mg/ml and 2mg/ml, respectively, and preparing mesalamine with 0.5% CMC-Na to obtain 50mg/mlThe suspension, beginning gavage at the same time as the model building, was subjected to gavage at a dose of 10. Mu.L/g (corresponding to administration doses of 10mg/kg, 20mg/kg and 50 mg/kg) for 10 days.
Mice weight changes were recorded daily and mice were sacrificed 10 days before sampling.
2. Determination of serum inflammatory factors
After 10 days of the administration, the mice were bled by taking an eye-ball, and after collecting whole blood, the blood was allowed to clot undisturbed at room temperature for 15 to 30 minutes. Serum was obtained by centrifugation at 1,000 Xg for 10min at 4 ℃ in a centrifuge. Serum samples were tested for IL-1 β and IL-23 serum levels using IL-1 β and IL-23ELISA kits available from Dake, inc.
3. Colon length measurement in mice
After blood was taken from the above eyeballs, the mice were sacrificed and the entire colon was photographed and length-measured.
4. Detection of inflammatory factor mRNA levels in colonic tissue
The colonic tissue was repeatedly washed with PBS, mucus was scraped off, the colonic mucosa of the mouse was separated, trizol was added to homogenize the tissue, the mixture was left to stand for 10min and centrifuged to obtain the supernatant, 1/5 volume of chloroform was added thereto and shaken for 1min, and the mixture was left to stand for 3min and centrifuged at 12000Xg at 4 ℃. And (3) adding isopropanol with the same volume into the supernatant, uniformly mixing, standing for 10min, centrifuging for 12000xg, and 10min. Removing supernatant, washing precipitate with 70% ethanol, centrifuging at 7500Xg for 5min, drying precipitate, and adding appropriate amount of DEPC water. And detecting the RNA concentration of the sample, adjusting the RNA concentration to 100-1000 ng/. Mu.L, and detecting the mRNA level of the corresponding inflammatory factor by using a commercial reverse transcription kit and a SYBR-qPCR kit.
5.RT-qPCR
According to the instructions of the reverse transcription kit, the following operations are carried out:
prepare the following mixture in RNase free centrifuge tube, gently blow and mix with a pipette. Incubate at 42 ℃ for 2min.
Preparation of reverse transcription reaction System (20. Mu.L System)
The cDNA was obtained and the working solution system was prepared according to the following table:
qPCR primers for each inflammatory factor are shown in the table below
Collecting instrument data, analyzing the data by adopting a 2-delta Ct method, and calculating the numerical value of the 2-delta Ct, namely the multiple of the target gene expression of the experimental group relative to the control group.
6. Inflammatory infiltration and mucosal injury observations
A colon of about 0.5cm in the middle section of the mouse is taken, fixed with paraformaldehyde at 4 ℃ for 16 hours, entrusted to Wuhan Seville biology company for paraffin embedding, sliced and stained with hematoxylin-eosin (H & E).
7. Pharmacokinetic experiments
18 mice (C57) were male, weighing 18-22g, and randomly divided into 6 groups of 3 mice, and the test compounds were gavaged with fasting for 12h before the test, with free water, and with a general meal 2h after the administration. The experimental protocol is as follows:
mice were collected in retro-orbital venous plexus blood collection in heparin sodium treated EP tubes and plasma was centrifuged according to the time points in the table. Accurately pipette 15. Mu.L of plasma into an EP tube corresponding to the sample number, add 300. Mu.L of a methanol/acetonitrile isometric mixed solution containing 50ng/mL tolbutamide (tolbutamide) as an internal standard, vortex the mixture for 1min, and centrifuge at 12000rpm for 10min at room temperature. Taking 35 mu L of supernatant andand mixing 65 mu L of acetonitrile/water equal-volume mixed solution uniformly, transferring the mixed solution into a 96-well plate, and performing LC-MS/MS analysis, wherein the injection volume is 2 mu L. Ultra performance liquid chromatography (Waters) was used for gradient separation, triple quadrupole mass spectrometry (API 5000, SCIEX) was used with an electrospray ion source, and detection was performed under negative ion conditions using a multiple reaction monitoring mode (MRM). Compound A 1 The calibration curve range is 1-3000 ng/mL.
The chromatographic conditions were as follows
A chromatographic column: waters Acquity C18 column (2.1 x 50mm,1.7 μm)
Column temperature: 45 deg.C
Mobile phase: MPA 0.1% formic acid in water
MPB 0.1% formic acid in acetonitrile/methanol (9/1, v/v)
Flow rate: 0.5mL/min
Gradient elution procedure:
the mass spectrum conditions were as follows
Compound Transition
A1 372.3>218.0
tolbutamide 269.2>169.8
8. Isolation and culture of colonic organoids
The whole colon of a mouse of 6 to 8 weeks old is cut from the middle, washed clean with precooled PBS, the small intestine is divided into segments of 5-8 cm long, mucus on the surface of the colon is scraped off with a glass slide, and the scraped colon is put into a 50mL centrifuge tube and placed on ice. The centrifuge tubes were transferred to a safety cabinet, washed 3-4 times with PBS containing the diabody, and the colon was transferred to 25ml of a solution of 2mM EDTA in a refrigerator at 4 ℃ for 25 minutes. Transferring the digested colon into a 50ml centrifuge tube, adding 25ml PBS containing the double antibody, properly shaking the colon under 50 ℃, filtering the suspension by using a 70um cell filter sieve, transferring the colon into a new centrifuge tube containing 25ml PBS containing the double antibody, continuously shaking the colon under 50, filtering the suspension by using a 70um cell filter sieve, transferring the suspension after twice filtration into the same 50ml centrifuge tube, and centrifuging the suspension at the room temperature under 900rpm for 5 minutes. The supernatant was discarded, the pellet was resuspended in 2mL of Advanced-DMEM/F12, and the appropriate amount of suspension was counted. The number of crypts is preferably 5-10 per ul. An appropriate volume of the suspension was added to a 1.5ml centrifuge tube and centrifuged at 900rpm for 5 minutes at room temperature. The pellet was resuspended with matrigel that was previously precooled on ice. The 96-well plates were pre-warmed in the incubator before 5ul of resuspension was plated per well. The inoculated plate is placed in an incubator for 10-15 minutes. 100ul of medium was added to each well, and then the medium was changed every 2-3 days.
The WNER medium consists of:
9. detecting the Effect of Compounds on organoid growth
According to the compound A 1 Preparing 50 mu M DMSO solution, adding organoid culture medium, taking pictures to observe the shape, sucking out the culture medium on day 7, cooling on ice for 10min to melt matrigel, and collecting organoids by PBS centrifugation. mRNA is extracted according to the above operation to detect the expression of the stem cell-related gene.
10. Data analysis
The data are analyzed by using SPSS 13.0, the comparison between two groups adopts pairing t test, the comparison between multiple groups adopts one-factor variance analysis, and P is less than 0.05, which is regarded as the difference of test results. Data are expressed as mean ± standard deviation (mean ± SD). Histogram and line plot were made with GraphPad Prism 7.0 software.
3. Results of the experiment
1. Cell test compound activity table
TABLE B
The inhibition rate calculation formula is as follows:
as shown in table B, experiments show that most of the compounds of the present invention have an inhibition rate of more than 50% (better than or equal to mesalazine) on IL-23mRNA, and most of the compounds have a certain upregulation effect on cyclinD1mRNA, wherein 19 compounds have an upregulation degree of more than 1.5. In addition, there were 14 compounds with an inhibition rate of IL-23mRNA of more than 50% (mean) and an upregulation effect of cyclinD1mRNA of more than 1.5 (mean). In contrast, the positive control drug mesalazine only inhibited IL-23mRNA expression, and showed no up-regulation or even slight down-regulation of cyclinD1mRNA (average of 0.9).
2. Results of animal experiments
FIG. 1 shows Compound A 1 Therapeutic effect on mouse colitis model. Wherein A is C57 mice modelled in DSS and administered orally simultaneously (10 mg/kg and 20mg/kg of Compound A) 1 And weight change during 50mg/kg mesalazine) (N = 5-7). B is a photograph of the colon and colon length statistics (N = 5-7) of the mice on day 7 of DSS modeling, 10 days after dosing. C is the result of mRNA expression detection of IBD-associated protein in colon tissue of mice. D is the result of ELISA detection of the level of the mouse serum inflammatory factor. E is mouse colon specimen H&E staining results, showing crypt destruction and inflammatory infiltration in the colon. * P is<0.05，**P<0.01，***P<0.001。
The results show that Compound A 1 Can improve DSS-induced IBD mice intestinal mucosa destruction and inflammatory infiltration dose-dependently, promote the weight recovery and colon length recovery of mice, reduce the levels of TNF alpha, IL-1 beta and IL-23 in peripheral blood and intestinal tracts and the mRNA expression level of inflammatory cytokines in intestinal tracts, and improve the mRNA expression level of cyclin D1. The above data indicate Compound A 1 Has obvious improvement effect on the condition of the acute IBD of the mice.
FIG. 2 shows Compound A 1 At both concentrations of 3mg/kg and 20mg/kg, the plasma concentrations of mice varied within 24h after the oral route of administration. The results showed that mice were orally administered 3mg/kg and 20mg/kg of Compound A 1 Post peak plasma concentration fraction175ng/mL,700ng/mL, with a peak time of approximately 1 hour; half-life of about 1.72 hours; the area under the curve was 410 (h ng/mL) and 2363 (h ng/mL), respectively, indicating a linear relationship between exposure and dose.
FIG. 3 shows Compound A 1 Promoting growth of mouse-derived intestinal organoids. Wherein A is the growth of mouse colon crypt isolates in Matrigel coated with WNER medium, compound A 1 Was 50 μ M, photographed using a Zeiss 710 live cell imager, and the organoid size and budding rate were counted and analyzed using Image J software (N = 5). B is intestinal stem cell marker gene detection by RNA extraction after organoids were collected on day 7 (N = 5). * P<0.05，**P<0.01，***P<0.001。
The results show that Compound A 1 Has obvious effect of promoting the growth of intestinal organoids from mice.
All documents mentioned in this application are incorporated by reference in this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Sequence listing
<110> Shanghai pharmaceutical research institute of Chinese academy of sciences
FUDAN University
<120> dihydrazide structure compound, preparation method and application thereof
<130> P2019-1393
<160> 15
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 1
ctgtccctgt atgcctctg 19
<210> 2
<211> 18
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 2
<210> 3
<211> 24
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 3
agtgtgaaga tggttgtgac ccac 24
<210> 4
<211> 24
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 4
gaagatgtca gagtcaagca ggtg 24
<210> 5
<211> 21
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 5
catgtacgtt gctatccagg c 21
<210> 6
<211> 21
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 6
ctccttaatg tcacgcacga t 21
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 7
<210> 8
<211> 19
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 8
cggtcgttga ggaggttgg 19
<210> 9
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 9
<210> 10
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 10
ataccccatc ccttttgagc 20
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 11
<210> 12
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 12
<210> 13
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 13
<210> 14
<211> 20
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 14
<210> 15
<211> 21
<212> DNA
<213> Artificial sequence (artificial sequence)
<400> 15
catcagaggc aaggaggaaa a 21
Claims (4)
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid methyl ester,
2- (2- (4-acetamidobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-benzoylaminobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropylcarbamoyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (trifluoromethoxy) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (trifluoromethyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (oxazol-5-yl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (6-chloronicotinyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (6-bromonicotinoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) -3-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) -2-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (2-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (3-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (3- (cyclopropanecarboxamido) -4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] hept-5-ene-2-carboxylic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclopropane-1-carboxylic acid,
4, 5-dibromo-2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid,
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) benzoic acid,
3- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (2-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2, 4-dichlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -2-naphthoic acid.
2. Use of a compound of formula III or a pharmaceutically acceptable salt thereof in the manufacture of a medicament and a pharmaceutical composition for the treatment or prevention of inflammatory bowel disease;
in the formula (I), the compound is shown in the specification,
q is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, C 1 -C 6 Haloalkyl, or-L 1 -M；
G is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 Alkylamino, hydroxymethyl, C 1 -C 6 Haloalkyl, or-L 1 -M；
A is independently selected from the group consisting of: substituted or unsubstituted C 3-12 Cycloalkyl, substituted or unsubstituted C 6 -C 14 Aryl, substituted or unsubstituted 6-14 membered heteroaryl; wherein the substitution is selected from one or more of the group consisting of: halogen, hydroxy, amino, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylamino, hydroxymethyl or C 1 -C 6 A haloalkyl group;
L 1 is-NHC (= O) -;
m is independently selected from the group consisting of: c 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy, substituted or unsubstituted C 3 -C 8 Cycloalkyl, substituted or unsubstituted C 6 -C 14 Aryl, substituted or unsubstituted 6-14 membered heteroaryl; and the substitution is selected from one or more of the group consisting of: halogen, nitro, cyano, C 1 -C 6 Alkyl radical, C 1 -C 6 Haloalkyl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Haloalkoxy, C 1 -C 6 An alkylamino group;
k is independently-C (= O) O-R 2 Wherein R is 2 Independently selected from the group consisting of: hydrogen, C 1 -C 6 An alkyl group.
3. Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament and a pharmaceutical composition for the treatment or prevention of inflammatory bowel disease, wherein the compound is selected from the group consisting of:
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid methyl ester,
2- (2- (4- (3-methylbutanamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-acetamidobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-benzoylaminobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclohexane carboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropylcarbamoyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (trifluoromethoxy) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (tert-butyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (trifluoromethyl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (oxazol-5-yl) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (3-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (2-chlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2, 4-dichlorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (6-chloronicotinyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (6-bromonicotinoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) -3-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) -2-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (2-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (3-chloro-4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (3- (cyclopropanecarboxamido) -4-fluorobenzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] hept-5-ene-2-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) benzoic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclopropane-1-carboxylic acid,
4, 5-dibromo-2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) cyclohexane-1-carboxylic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid,
2- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -3, 6-difluorobenzoic acid,
2- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) benzoic acid,
3- (2- (4-fluorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (4-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (3-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (2-chlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2, 4-dichlorobenzoyl) hydrazine-1-carbonyl) bicyclo [2.2.1] heptane-2-carboxylic acid,
3- (2- (4- (cyclopropanecarboxamido) benzoyl) hydrazine-1-carbonyl) -2-naphthoic acid.
4. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911089415.XA CN112778156B (en) | 2019-11-08 | 2019-11-08 | Bishydrazide structure compound, preparation method and application thereof |
| PCT/CN2020/127252 WO2021089011A1 (en) | 2019-11-08 | 2020-11-06 | Compound with bishydrazide structure, and preparation method therefor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911089415.XA CN112778156B (en) | 2019-11-08 | 2019-11-08 | Bishydrazide structure compound, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112778156A CN112778156A (en) | 2021-05-11 |
| CN112778156B true CN112778156B (en) | 2023-03-14 |
Family
ID=75748534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911089415.XA Active CN112778156B (en) | 2019-11-08 | 2019-11-08 | Bishydrazide structure compound, preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112778156B (en) |
| WO (1) | WO2021089011A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113527153B (en) * | 2020-04-20 | 2023-01-06 | 中国科学院上海药物研究所 | Active compound for inhibiting intestinal inflammatory reaction |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964896A (en) * | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| RO116620B1 (en) * | 1997-12-22 | 2001-04-30 | Ct De Cercetare Si Productie B | N 1 - acyl - n 2 - (o - carboxybenzoyl) -hydrazine and process for preparing the same |
| CN101668732A (en) * | 2007-04-02 | 2010-03-10 | 同一世界健康研究院 | CFTR inhibitor compound and uses thereof |
| CN102775381A (en) * | 2011-05-13 | 2012-11-14 | 中国科学院上海药物研究所 | Substituted hydrazide compound, and its preparation method, medicinal compositions and application |
| WO2015125785A1 (en) * | 2014-02-18 | 2015-08-27 | 第一三共株式会社 | Pyrazolone derivative having multiple substituents |
| WO2018150755A1 (en) * | 2017-02-16 | 2018-08-23 | 株式会社Adeka | Novel compound, nucleating agent, resin composition, and molded article |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000027835A1 (en) * | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| CA2548571A1 (en) * | 2003-12-10 | 2005-06-30 | Merck Patent Gmbh | Diacylhydrazine derivatives |
| EP2204379A4 (en) * | 2007-10-29 | 2010-12-22 | Astellas Pharma Inc | Polypeptide compound |
| EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8785499B2 (en) * | 2009-07-10 | 2014-07-22 | University Of Maryland, Baltimore | Targeting NAD biosynthesis in bacterial pathogens |
| RU2412160C1 (en) * | 2009-09-25 | 2011-02-20 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) | 7-[n'-(4-trifluoromethylbenzolyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid, having antiviral activity |
| CN104557691B (en) * | 2014-12-11 | 2017-10-24 | 中国农业大学 | A kind of 3 amine acyl bishydrazide derivatives and its preparation method and application |
-
2019
- 2019-11-08 CN CN201911089415.XA patent/CN112778156B/en active Active
-
2020
- 2020-11-06 WO PCT/CN2020/127252 patent/WO2021089011A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3964896A (en) * | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| RO116620B1 (en) * | 1997-12-22 | 2001-04-30 | Ct De Cercetare Si Productie B | N 1 - acyl - n 2 - (o - carboxybenzoyl) -hydrazine and process for preparing the same |
| CN101668732A (en) * | 2007-04-02 | 2010-03-10 | 同一世界健康研究院 | CFTR inhibitor compound and uses thereof |
| CN102775381A (en) * | 2011-05-13 | 2012-11-14 | 中国科学院上海药物研究所 | Substituted hydrazide compound, and its preparation method, medicinal compositions and application |
| WO2015125785A1 (en) * | 2014-02-18 | 2015-08-27 | 第一三共株式会社 | Pyrazolone derivative having multiple substituents |
| WO2018150755A1 (en) * | 2017-02-16 | 2018-08-23 | 株式会社Adeka | Novel compound, nucleating agent, resin composition, and molded article |
| TW201831442A (en) * | 2017-02-16 | 2018-09-01 | 日商艾迪科股份有限公司 | Novel compound, nucleating agent, resin composition, and molded article |
Non-Patent Citations (4)
| Title |
|---|
| Reaction of phthalic anhydride with carboxylic acid hydrazides;Unishi, Terunobu;《Nippon Kagaku Zasshi》;19661231;第87卷(第11期);第1217-1220页 * |
| Synthesis and spectra of some phthalimido derivatives;El Sadek, Mohamed M.等;《Journal of Chemical and Engineering Data 》;19891231;第34卷(第2期);第257-259页 * |
| Synthesis of 3-amino-3,4-dihydroquinazolin-4-one derivatives from anthranilic acid hydrazide and dicarboxylic acids;Shemchuk, L. A.等;《Russian Journal of Organic Chemistry》;20071231;第43卷(第12期);第1830-1835页 * |
| 组氨酸蛋白激酶抑制剂对福氏志贺菌毒力影响的初步研究;陈明亮等;《复旦学报（医学版）》;20071231;第34卷(第3期);第317-322页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112778156A (en) | 2021-05-11 |
| WO2021089011A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106536520B (en) | Aryl receptor modulators and methods of making and using the same | |
| CN108250122B (en) | Sulfonamide-aryl amide compounds and pharmaceutical use thereof for treating hepatitis B | |
| BR102018002164A2 (en) | compounds for the treatment of hepatitis b virus infection | |
| WO2019011323A1 (en) | Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis b | |
| CN111107848A (en) | Pharmaceutical composition containing amide derivatives, and preparation method and application thereof | |
| EP3162801B1 (en) | Salt of halogen-substituted heterocyclic compound | |
| WO2018202155A1 (en) | Bicyclic nucleocapsid inhibitor and use of same as drug in treatment of hepatitis b | |
| US11655237B2 (en) | Solid forms of a Cot inhibitor compound | |
| CN112955143A (en) | Treatment of non-alcoholic fatty liver disease | |
| CN112778156B (en) | Bishydrazide structure compound, preparation method and application thereof | |
| WO2018133845A1 (en) | Thiourea and urea compound and use thereof | |
| KR102650441B1 (en) | Internally cyclic sulfiamidine amide-aryl amide compounds and their use for the treatment of hepatitis B | |
| CN112243437A (en) | Acryloyl group-containing nuclear transport modulators and uses thereof | |
| CN115197207B (en) | Tetrahydro-gamma-carboline derivatives, pharmaceutical composition and application thereof | |
| CN112996507B (en) | Treatment of obesity | |
| WO2021057994A1 (en) | Pyrazole compound and use thereof | |
| WO2019114543A1 (en) | Crystal form of pde-5 inhibitor | |
| CN113527153B (en) | Active compound for inhibiting intestinal inflammatory reaction | |
| CN116283993B (en) | Pyrimidine compound and preparation method and application thereof | |
| TWI839385B (en) | Treatment of Obesity | |
| WO2022152140A1 (en) | Bridged heterocyclyl-substituted pyrimidine compounds, preparation method and medical use thereof | |
| CN115244054A (en) | Crystals of hypoxanthine compound | |
| CN109134600B (en) | Alkyl and heterocyclic compounds as hepatitis C inhibitors and application thereof in medicines | |
| CN115611808A (en) | Novel inhibitor of enterovirus D68 type, preparation method and application thereof | |
| WO2020233716A1 (en) | Imidazopyridazine mnk1/mnk2 kinase inhibitors, preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |